CLOSE X

ERIS LIFESCIENCES LTD.

NSE : ERISBSE : 540596ISIN CODE : INE406M01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE1794.304.05 (+0.23 %)
PREV CLOSE ( ) 1790.25
OPEN PRICE ( ) 1755.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13634
TODAY'S LOW / HIGH ( )1734.55 1815.80
52 WK LOW / HIGH ( )988.95 1909.55
NSE1795.104 (+0.22 %)
PREV CLOSE( ) 1791.10
OPEN PRICE ( ) 1764.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1795.10 (2)
VOLUME 274234
TODAY'S LOW / HIGH( ) 1731.60 1816.70
52 WK LOW / HIGH ( )987.1 1910
GO
(Rs.in Million)
Particulars
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Audited / UnAudited
UnAudited
UnAudited
UnAudited
UnAudited
Net Sales
7053.00
7274.50
7411.70
7197.20
Total Expenditure
4529.10
4771.40
4766.60
4697.30
PBIDT (Excl OI)
2523.90
2503.10
2645.10
2499.90
Other Income
79.50
42.20
45.50
16.40
Operating Profit
2603.40
2545.30
2690.60
2516.30
Interest
542.80
571.70
594.70
603.70
Exceptional Items
NA
NA
NA
NA
PBDT
2060.60
1973.60
2095.90
1912.60
Depreciation
772.50
812.00
804.80
759.40
Profit Before Tax
1288.10
1161.60
1291.10
1153.20
Tax
265.20
292.30
327.60
259.00
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
1022.90
869.30
963.50
894.20
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
NA
NA
NA
NA
Net Profit
1022.90
869.30
963.50
894.20
Minority Interest
-85.10
-33.00
-47.60
-62.40
Shares of Associates
0.6
Other related items
Misc. Expenses Written off
NA
NA
NA
NA
Consolidated Net Profit
938.40
836.30
915.90
831.80
Equity Capital
136.20
136.10
136.10
136.10
Face Value (IN RS)
1.00
1.00
1.00
1.00
Reserves
NA
NA
NA
NA
Calculated EPS
6.89
6.14
6.73
6.11
Calculated EPS (Annualised)
27.56
24.58
26.92
24.45
No of Public Share Holdings
61478825.00
61445538.00
61422048.00
61391264.00
% of Public Share Holdings
45.15
45.14
45.13
45.12
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
35.78
34.41
35.69
34.73
PBIDTM%
36.91
34.99
36.30
34.96
PBDTM%
29.22
27.13
28.28
26.57
PBTM%
18.26
15.97
17.42
16.02
PATM%
14.50
11.95
13.00
12.42
 
Notes
Notes
Notes
Notes
ATTENTION INVESTORS NSDL/CDSL KYC Advisory for investors